Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2CNS 1

Conditions

Prostatic Neoplasms 86Lung Neoplasms 64Carcinoma, Non-Small-Cell Lung 50Neoplasm Metastasis 48Breast Neoplasms 48Glioma 41Glioblastoma 38Pancreatic Neoplasms 35Multiple Myeloma 35Brain Neoplasms 34Carcinoma, Renal Cell 33Lymphoma, Large B-Cell, Diffuse 29Melanoma 28Urinary Bladder Neoplasms 27Colorectal Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 21Oropharyngeal Neoplasms 21Carcinoma, Hepatocellular 21Lymphoma 20Mouth Neoplasms 18Lymphoma, Follicular 18Sarcoma 17Fallopian Tube Neoplasms 16Carcinoma, Transitional Cell 16Carcinoma 16Laryngeal Neoplasms 15Astrocytoma 15Lymphoma, Mantle-Cell 14

Interventions

Specimen Handling 5Genetic Testing 3Surveys and Questionnaires 2Magnetic Resonance Spectroscopy 2Genetic Counseling 2Endoscopy 2Colonoscopy 2Biopsy 2Aspirin 2pembrolizumab 1dehydroftorafur 1atezolizumab 1acetylsalicylic acid lysinate 1Secretin 1RAD51C protein, human 1Oxaliplatin 1Nivolumab 1Naproxen 1Liquid Biopsy 1Leucovorin 1Ipilimumab 1Interviews as Topic 1High-Throughput Nucleotide Sequencing 1Hematologic Tests 1Health Promotion 1G-T mismatch-binding protein 1Fluorouracil 1Endoscopic Mucosal Resection 1Educational Status 1Diffusion Tensor Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Neoplasms, Hereditary Nonpolyposis × Magnetic Resonance Spectroscopy × 1 year × Clear all
NCT02912559 2026-06-01

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

National Cancer Institute (NCI)

Phase 3 Active not recruiting
712 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡